nL-FLVC-001
- Generic Name
- nL-FLVC-001
Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
Early Phase 1
- Conditions
- Posterior Column Ataxia with Retinitis Pigmentosa
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 1
- Registration Number
- NCT06565572
- Locations
- 🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath